What is the preferred sequence of systemic therapy in a patient with endocrine resistant HR+ metastatic breast cancer?  

The patient previously received endocrine therapy alone and in combination with CDK 4/6 inhibitor. She does not have any targetable mutations on NGS. What factors would impact your treatment decision?

Answer from: Medical Oncologist at Community Practice